Repurposing FDA-approved drugs to combat drug-resistant Acinetobacter baumannii

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 12, 2010, Pages 2598-2601

  Chopra, Sidharth ^a   Torres Ortiz, Maria ^a   Hokama, Leslie ^a   Madrid, Peter ^a   Tanga, Mary ^a   Mortelmans, Kristien ^a   Kodukula, Krishna ^a   Galande, Amit K ^a  

^a SRI INTERNATIONAL   (United States)

Author keywords

Cyclic peptides; Gram negative infections; Tyrothricin

Indexed keywords

ANTIBIOTIC AGENT; DEMECLOCYCLINE; DOXYCYCLINE; ENROFLOXACIN; FLUMEQUINE; GATIFLOXACIN; GEMIFLOXACIN; HEXACHLOROPHENE; KANAMYCIN A; LEVOFLOXACIN; LOMEFLOXACIN; MINOCYCLINE; MOXIFLOXACIN; NORDIFLOXACIN; OFLOXACIN; OXOLINIC ACID; PEFLOXACIN; POLYMYXIN; POLYMYXIN B; RIFAXIMIN; THIOMERSAL; TYROTHRICIN;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; DRUG APPROVAL; DRUG SCREENING; FOOD AND DRUG ADMINISTRATION; GRAM POSITIVE BACTERIUM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; CROSS INFECTION; DRUG APPROVAL; DRUG DISCOVERY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; TYROTHRICIN; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 78149483881     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq353     Document Type: Article

References (10)

1. Boucher HW, Talbot GH, Bradley JS et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 1-2.
2. Lockhart SR, Abramson MA, Beekmann SE et al. Antimicrobial resistance among Gram-negative bacilli causing infections in intensive care unit patients in the United States between 1993 and 2004. J Clin Microbiol 2007; 45: 3352-9.
3. Fischbach MA, Walsh CT. Antibiotics for emerging pathogens. Science 2009; 325: 1089-93.
4. Boguski MS, Mandl KD, Sukhatme VP. Drug discovery. Repurposing with a difference. Science 2009; 324: 1394-5.
5. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Seventeenth Informational Supplement M100-S17. CLSI, Wayne, PA, USA, 2007.
6. Fournier PE, Vallenet D, Barbe V et al. Comparative genomics of multidrug resistance in Acinetobacter baumannii. PLoS Genet 2006; 2: e7.
7. Coelho JM, Turton JF, Kaufmann ME et al. Occurrence of carbapenem-resistant Acinetobacter baumannii clones at multiple hospitals in London and Southeast England. J Clin Microbiol 2006; 44: 3623-7.
8. Seward RJ, Towner KJ. Molecular epidemiology of quinolone resistance in Acinetobacter spp. Clin Microbiol Infect 1998; 4: 248-54.
9. Tang XJ, Thibault P, Boyd RK. Characterization of the tyrocidine and gramicidin fractions of the tyrothricin complex from Bacillus brevis using liquid chromatography and mass spectrometry. Int J Mass Spectrom Ion Process 1992; 122: 153-79.
10. Urban C, Mariano N, Rahal JJ et al. Polymyxin B-resistant Acinetobacter baumannii clinical isolate susceptible to recombinant BPI and cecropin P1. Antimicrob Agents Chemother 2001; 45: 994-5.